OOIR: Observatory of International Research

Papers

(The TQCC of Pituitary is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Lateral orientation of Rathke cleft cysts may be associated with high rates of recurrence after surgery	85
Reported outcomes in transsphenoidal surgery for pituitary adenomas: a systematic review	63
Evaluation of cardiac structure, exercise capacity and electrocardiography parameters in children with partial and complete growth hormone deficiency and their changes with short term growth hormone r	40
Cushing’s disease: role of bilateral adrenalectomy	36
Idiopathic central diabetes insipidus in a large cohort of patients: the hypopituitarism ENEA rare observational (HEROS) study	36
Pituitary stalk interruption syndrome: phenotype, predictors, and pathophysiology of perinatal events	33
Diffusion-weighted imaging does not seem to be a predictor of consistency in pituitary adenomas	30
The efficacy of a visiting surgical service versus that of a hospital-based surgical service in providing endoscopic endonasal surgery to remove nonfunctioning pituitary adenomas in rural communities	29
Semaglutide treatment of hypothalamic obesity – a real-life data study	26
The impact of facility type and volume on treatment and overall survival in craniopharyngioma	26
Surgical treatment of cystic pituitary adenomas: literature-based definitions and postoperative outcomes	24
Changing the name of diabetes insipidus	23
Skeletal fragility in pituitary disease: how can we predict fracture risk?	22
Delayed postoperative hyponatremia in patients with acromegaly: incidence and predictive factors	22
Hypercoagulability in Cushing’s syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols	22
Growth hormone insensitivity and adipose tissue: tissue morphology and transcriptome analyses in pigs and humans	21
An Infundibular Unidentified Object (IUO): a new pituitary stalk marker?	21
Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists	21
Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need	21
Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis	21
When to decide on testosterone replacement despite dopamine agonist therapy in male prolactinomas?	20
Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers	19
Pituitary tumor centers of excellence (PTCOE): the next border of acromegaly treatment	19
The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications	18
Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas	18

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results	18
Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency	18
Historical and future trends in emergency pituitary referrals: a machine learning analysis	18
Measuring pituitary tumor volume: a comparison of the simplified and non-simplified ellipsoid equation with the 3D planimetric volume assessment	18
Assessment of forearm muscles with ultrasound shear wave elastography in patients with acromegaly	17
A comparison of macular ganglion cell and retinal nerve fibre layer optical coherence tomographic parameters as predictors of visual outcomes of surgery for pituitary tumours	17
Demonstration of the inferior intercavernous sinus is closely linked to the extent of pneumatization of the sphenoid sinus: useful information for the pituitary surgeon	16
Development of a cost-effective diagnostic algorithm incorporating transcription factor immunohistochemistry in the evaluation of pituitary tumours	16
Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma	16
GnRH agonist-associated pituitary apoplexy: a case series and review of the literature	15
Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States	15
Growth hormone increase by luteinizing hormone-releasing hormone reflects gonadotroph-related characteristics in acromegaly	15
Growth hormone secreting pituitary adenomas show distinct extrasellar extension patterns compared to nonfunctional pituitary adenomas	14
Influence of growth hormone therapy on germinoma survivors	14
Medical therapy for refractory pituitary adenomas	14
Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly	14
Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists	14
The impact of non-clinical factors in pituitary surgery	13
Predictors of biochemical remission after transsphenoidal surgery in a large cohort of acromegaly patients	13
Substance P and Neurokinin-1 receptor are overexpressed in adamantinomatous craniopharyngioma than in the pituitary gland	13
Importance of 24 h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings	13
Headache relief following endoscopic drainage of Rathke’s cleft cyst	12
Treatment and prognostic factors of pituicytoma: a single-center experience and comprehensive literature review	12
A study on clinical outcomes of Rathke’s cleft cyst in patients managed conservatively	12
Pituitary apoplexy score, toward standardized decision-making: a descriptive study	12
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience	12
Machine learning models predict delayed hyponatremia post-transsphenoidal surgery using clinically available features	11
Posterior hypothalamic involvement on pre-operative MRI predicts hypothalamic obesity in craniopharyngiomas	11
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study	11
Diabetes insipidus after endoscopic transsphenoidal surgery: multicenter experience and development of the SALT score	11
An update on, and genetics of refractory adenomas of childhood	11
Pituitary metastases: a case series and scoping review	11
Cushing’s disease: adrenal steroidogenesis inhibitors	11
Comparison between extended transsphenoidal and transcranial surgery for craniopharyngioma: focus on hypothalamic function and obesity	11
TGFBR3L is associated with gonadotropin production in non-functioning gonadotroph pituitary neuroendocrine tumours	11
Giant prolactinomas, a detailed analysis of 196 adult cases	10
Can we predict the risk of venous thromboembolism in patients with Cushing’s syndrome: a nationwide cohort analysis	10
Correction: Giant prolactinomas, a detailed analysis of 196 adult cases	10
Changes in pituitary adenoma patient presentation and outcomes during the COVID pandemic at a Pituitary Center of Excellence	10
The role of BRAF testing of Rathke’s cleft cysts to identify missed papillary craniopharyngioma	10
Hospital frailty risk score predicts postoperative outcomes after endoscopic endonasal resection of non-functioning pituitary adenomas	10
Exploring sex-specific hematological changes and their impact on quality of life in patients with prolactinoma	10
Treatment of acromegaly-induced diabetes: an updated proposal	10
Sheehan syndrome: a current approach to a dormant disease	10
Effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: an updated systematic review and meta-analysis	10
Inflammation of adenohypophysis is commonly associated with headache in surgically managed Rathke’s cleft cysts	10
Cushing’s disease: role of preoperative and primary medical therapy	10
Problem-solving therapy can reduce psychological distress in patients with Cushing’s disease: a randomized controlled trial	9
Second-line regimen for CNS-involved pediatric Langerhans cell histiocytosis	9
Overnight 1 mg dexamethasone suppression test and 24 h urine free cortisol—accuracy and pitfalls when screening for Cushing’s syndrome	9

A patient-reported outcome measure for patients with pituitary adenoma undergoing transsphenoidal surgery	9
Pituitary: hic manebimus optime	9
Symptoms and steroid dose adjustments following the Covid-19 vaccine in patients with adrenal insufficiency	9
Acromegaly increases depressive symptoms and reduces quality of life of cohabitants	8
Sleep disruption in patients with active and treated endogenous Cushing’s syndrome	8
11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy	8
Evaluating the burden of endogenous Cushing’s syndrome using a web-based questionnaire and validated patient-reported outcome measures	8
Refractory pituitary adenomas: preface	8
Vertebral fractures in patients with non-functioning pituitary adenomas - a new frontier?	8
The somatotroph pituitary gland function in high-aged multimorbid hospitalized patients with IGF-I deficiency	8
Refractory lactotroph adenomas	8
Prevalence of coronary calcium deposits in Sheehan’s syndrome patients on long term replacement treatment	8
Endoscopic endonasal marsupialization of rathke cleft cysts: clinical outcomes and risk factors analysis of visual impairment, pituitary dysfunction, and CSF leak	8
Natural history of untreated microprolactinomas	8
High prevalence of overweight/obesity and dyslipidemia in patients with intracranial germ cell tumors	8
Cardiovascular risk and glucocorticoids: a Dutch National Registry of growth hormone treatment in adults with growth hormone deficiency analysis	7
Thyrotropin-secreting pituitary adenomas induce left atrial enlargement with subclinical atrial fibrillation: an echocardiographic study	7
Venous thromboembolism chemical prophylaxis after endoscopic trans-sphenoidal pituitary surgery	7
Neuropathic foot ulcers in the tallest patients with acromegalic gigantism: a common and significant problem. Historical overview	7
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience	7
Basal cortisol in relation to metyrapone confirmation in predicting adrenal insufficiency after pituitary surgery	7
Double adenomas of the pituitary reveal distinct lineage markers, copy number alterations, and epigenetic profiles	7
Radiological evolution of autograft fat used for skull base reconstruction after transsphenoidal surgery for pituitary adenomas	7
Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2	7
Postsurgical outcomes of nonfunctioning pituitary adenomas: a patient-level meta-analysis	7
Different patient versus provider perspectives on living with Cushing’s disease	7
Novel approach to bone comorbidity in resistant acromegaly	7
Acromegaly and pregnancy: a systematic review and meta-analysis	7
Discrimination between non-functioning pituitary adenomas and hypophysitis using machine learning methods based on magnetic resonance imaging‑derived texture features	7
HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency	7
Impact of etiology, sex, diabetes mellitus and remission status on erythrocytic profile in patients with cushing’s syndrome: a large population database study	7
Acute elevation of interleukin 6 and matrix metalloproteinase 9 during the onset of pituitary apoplexy in Cushing’s disease	7